Semaglutide for fatty liver has strong evidence in one defined group: adults with noncirrhotic MASH and F2–F3 fibrosis. It is not a blanket answer for anyone with fat seen on an ultrasound. In ESSENCE, weekly semaglutide 2.4 mg improved both biopsy-based endpoints at 72 weeks versus placebo, and in August 2025 the FDA granted Wegovy accelerated approval for that group. The evidence belongs to the branded drug, studied dose and diagnosed disease stage—not to every semaglutide preparation or to simple steatosis.
What “fatty liver” means now
The language changed in 2023. A 236-member international panel replaced nonalcoholic fatty liver disease, or NAFLD, with metabolic dysfunction-associated steatotic liver disease, or MASLD. NASH became metabolic dysfunction-associated steatohepatitis, or MASH (Rinella et al., Journal of Hepatology 2023).
Those terms describe different points on a spectrum. MASLD means liver fat plus at least one cardiometabolic risk factor. MASH adds liver-cell injury and inflammation. Fibrosis is the scar tissue that can follow; stages F2 and F3 mean moderate and advanced fibrosis, while F4 is cirrhosis. That distinction matters because the trial evidence and the Wegovy indication concern MASH with F2–F3 fibrosis—not every case described casually as fatty liver.
What trials show about semaglutide for fatty liver
ESSENCE is an ongoing phase 3 trial of 1,197 adults with biopsy-confirmed MASH and F2–F3 fibrosis. Its planned 72-week interim analysis covered the first 800 participants. MASH resolved without worsening fibrosis in 62.9% of the semaglutide group and 34.3% of the placebo group. Fibrosis improved by at least one stage without worsening MASH in 36.8% and 22.4%, respectively (Sanyal et al., NEJM 2025).
The earlier phase 2 trial explains why those two endpoints both matter. Among 320 participants, MASH resolution without worsening fibrosis occurred in 59% at the highest studied semaglutide dose and 17% with placebo. Fibrosis improved in 43% and 33%, a difference that was not statistically significant. That trial found a clear inflammation signal, but not a conclusive fibrosis result (Newsome et al., NEJM 2021). ESSENCE later met both histology endpoints. Neither interim biopsy result yet proves fewer cases of liver failure, transplant or death; ESSENCE continues to 240 weeks to measure clinical outcomes.
What the August 2025 approval actually covers
On August 15, 2025, the FDA granted Wegovy accelerated approval for adults with noncirrhotic MASH and moderate-to-advanced fibrosis consistent with F2–F3. As of August 2026, the indication remains on the agency’s ongoing accelerated-approval record, with the full ESSENCE outcome study required to confirm clinical benefit. It is not a general indication for simple liver fat or cirrhosis.
Promise dispenses semaglutide as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A branded indication does not transfer automatically to a compounded preparation. Regulatory status is one input into care, and a licensed provider may still prescribe a compounded formulation when appropriate; that decision is between the patient and the doctor.
Why tirzepatide enters the same conversation
Tirzepatide has separate, earlier-stage MASH evidence. In the 190-participant SYNERGY-NASH phase 2 trial, MASH resolution without worsening fibrosis at 52 weeks occurred in 44%, 56% and 62% across its three dose groups, compared with 10% on placebo. At least one-stage fibrosis improvement without worsening MASH occurred in 51%–55% versus 30% (Loomba et al., NEJM 2024).
That was not a head-to-head study with semaglutide. It makes tirzepatide relevant to a clinician weighing metabolic treatment options, but it cannot establish which medication is better for an individual liver diagnosis.
How semaglutide may affect the liver
Semaglutide activates the GLP-1 receptor. Its better-established effects include reduced energy intake, weight loss and improved glucose regulation; how semaglutide works explains that pathway, while semaglutide for type 2 diabetes covers the glycemic evidence. Less adipose-tissue insulin resistance and lower fatty-acid delivery to the liver offer a coherent indirect route to less liver fat and metabolic stress.
A direct liver-cell effect is not settled. A 2024 laboratory study—not a semaglutide trial—found no meaningful GLP-1 or GIP receptor signaling and no direct drug response in primary human hepatocytes or hepatic stellate cells (da Silva Lima et al., Cellular and Molecular Life Sciences 2024). The clinical results are real; the safest mechanistic reading is that systemic metabolic changes carry much of the effect.
What a prescriber checks before connecting the evidence to a patient
An ultrasound can show liver fat, but it cannot by itself establish MASH or stage fibrosis. A prescriber reviews the cause and severity rather than treating the phrase “fatty liver” as a diagnosis.
| Question | What may inform it |
|---|---|
| Is metabolic dysfunction present? | Weight history, type 2 diabetes, blood pressure and lipids |
| Is advanced scarring plausible? | Age, AST, ALT and platelet count combined in a FIB-4 score |
| What is the fibrosis stage? | Elastography, ELF blood testing, magnetic resonance elastography or specialist assessment |
| Is cirrhosis present? | Imaging, noninvasive tests, platelet count and hepatology review |
The November 2025 AASLD update says candidates with F2–F3 fibrosis can often be identified with noninvasive tests rather than a mandatory biopsy. It also keeps nutrition, physical activity and management of diabetes, blood pressure and lipids in the care plan. A normal or mildly abnormal enzyme result cannot answer the fibrosis question by itself.
The trial result and the prescription are separate decisions
A trial asks what happened to a defined group under a fixed protocol. A clinical review asks whether one person matches that group, whether another liver disease needs attention, what other medications are involved and whether the likely risks fit the goal. The prescriber sets the actual dose. Semaglutide side effects and the distinction between branded and compounded semaglutide belong in that review.
At Promise, a licensed provider reviews every request and prescribes only when semaglutide is appropriate. Not everyone qualifies.
The useful conclusion is narrow: Wegovy has phase 3 histology evidence and an accelerated indication for noncirrhotic MASH with F2–F3 fibrosis. A diagnosis and fibrosis stage—not the words fatty liver alone—determine whether that evidence applies.